Core Viewpoint - In the first five months of this year, 610 out of 999 comparable ordinary stock funds achieved positive performance, with a notable focus on biopharmaceutical-themed funds leading the gains [1][2]. Group 1: Performance of Funds - Biopharmaceutical-themed funds dominated the performance rankings, with top funds like Zhongyin Health Stock A and C, Penghua Pharmaceutical Technology Stock A and C, and Huaan Pharmaceutical Biotechnology Stock A and C showing significant increases of 56.21%, 55.95%, 53.93%, 53.67%, 52.83%, and 52.59% respectively [1][3]. - Zhongyin Health Stock's top ten holdings in Q1 included major pharmaceutical companies such as Heng Rui Pharmaceutical and Bai Li Tianheng, with some stocks like Rongchang Biotechnology doubling in value [1][2]. - Other funds like Jiashi Mutual Selection Stock A and C also reported impressive gains of 50.71% and 50.46%, respectively, despite not being biopharmaceutical-focused, as their top holdings were also in the pharmaceutical sector [2][3]. Group 2: Underperforming Funds - Funds focused on technology manufacturing, chips, new materials, and new energy significantly lagged, with declines such as 21.10% for Caitong Integrated Circuit Industry Stock C and 20.84% for Caitong Integrated Circuit Industry Stock A [3][4]. - The top holdings of these underperforming funds included companies like SMIC and Tencent, indicating a challenging environment for technology-focused investments in the current market [3][4]. Group 3: Fund Management Insights - Zhongyin Health Stock has been managed by Zheng Ning since 2022, who has extensive experience in pharmaceutical research and fund management [1][2]. - Penghua Pharmaceutical Technology Stock is managed by veteran Jin Xiaofei, who has nearly nine years of experience in the industry [2][3]. - Jiashi Mutual Selection Stock's manager, Hao Miao, has a strong background in biochemistry and has transitioned from research roles to fund management, contributing to the fund's performance [2][3].

Group 1 - In May, 696 out of 1025 comparable ordinary equity funds achieved positive performance, representing 68% of the total [1] - The pharmaceutical-themed funds led the performance, with 15 funds showing monthly gains exceeding 10%, including Anxin Pharmaceutical Health Stock A and C, and Hongtu Innovation Medical Care Stock [1] - Anxin Pharmaceutical Health Stock A and C had gains of 15.35% and 15.31% respectively, while Hongtu Innovation Medical Care Stock gained 15.01% [1] Group 2 - Penghua Pharmaceutical Technology Stock A and C increased by 12.44% and 12.40% respectively, managed by veteran fund manager Jin Xiaofei [2] - Other notable pharmaceutical-themed funds with significant gains include Jianxin Medical Health Industry Stock and Invesco Great Wall Medical Industry Stock [2] - Funds heavily invested in technology stocks, such as Huian Trend Power Stock A and C, underperformed with declines of 9.74% and 9.69% respectively [2] Group 3 - Funds focused on advanced manufacturing and semiconductor industries, such as GF Advanced Manufacturing Stock and Chuangjin Hexin Chip Industry Stock, experienced declines ranging from 8.56% to 7.09% [3] - The top holdings of GF Advanced Manufacturing Stock include leading companies in manufacturing and technology sectors [3] - Financial performance of the funds in the semiconductor sector showed significant changes, with some funds experiencing a net value drop of 13.98% in the first quarter [3] Group 4 - The performance rankings of ordinary equity funds in May highlighted the top gainers and losers, with Anxin Pharmaceutical Health Stock A leading the gains [4] - The data indicates a clear trend where pharmaceutical funds outperformed technology-focused funds during this period [4] - The overall market sentiment reflected a preference for healthcare-related investments amid broader market fluctuations [4]

中国经济网北京5月7日讯 （记者 康博） 今年4月份，在有可比业绩的1016只普通股票型基金中，业绩 实现上涨的共有171只，另有3只持平，842只下跌。 医药与生物制药行业成为领涨板块，也让此类主题基金业绩遥遥领先。数据显示，4月份涨幅超过10% 的普通股票型基金有中银大健康股票A、中银大健康股票C、鹏华医药科技股票A、鹏华医药科技股票 C、华安医药生物股票发起式A、华安医药生物股票发起式C。 中银大健康股票A、C以12.65%、12.61%位居榜首，今年一季报显示，该基金前十大重仓股为恒瑞医药 （600276）、新诺威（300765）、百利天恒、百济神州、诺诚健华、荣昌生物、海思科（002653）、信 立泰（002294）、科伦药业（002422）、康诺亚。 汇丰晋信低碳先锋股票A、C在4月份跌幅达10.07%、10.11%，其前十大重仓股全部为新能源个股，包 括明阳智能（601615）、通威股份（600438）、隆基绿能（601012）、亿纬锂能（300014）、华友钴业 （603799）、晶澳科技（002459）、东方日升（300118）、恩捷股份（002812）、固德威、杭可科技。 值得注意的是，汇 ...